MAPK3 and lung cancer: Overall, our results demonstrate that silencing ARL14 can block ERK1/2 and p38 signaling and stimulates its downstream gene CIDEC expression, which further activates their downstream effectors of p16, p21, p27, p53, and cyclin D1, resulting in cell cycle arrest of the lung cancer cells.